OncoMatch/Clinical Trials/NCT04547049
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
Is NCT04547049 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for leukemia.
Treatment: Cytarabine · Busulfan · Cyclophosphamide · Me-CCNU · Rabbit antithymocyte globulin · Cyclosporin A · Mycophenolate Mofetil · MTX — An open, multi-center, randomized trial comparing haploidentical HSCTs from young non-first-degree and older first-degree donors in hematological malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: allogeneic hematopoietic cell transplant — first
A first allo-HCT
Cannot have received: allogeneic hematopoietic cell transplant
Not the first allo-HCT
Lab requirements
Kidney function
No severe kidney insufficiency
Liver function
No severe liver insufficiency
Cardiac function
No severe heart insufficiency
Patients with severe heart, lung, liver and kidney insufficiency [excluded]; Adequate end-organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify